|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
PT1523496E
(pt)
|
2002-07-18 |
2011-09-29 |
Merus B V |
Produção de misturas de anticorpos de forma recombinante
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
EP1639009B1
(en)
|
2003-05-30 |
2013-02-27 |
Merus B.V. |
Fab library for the preparation of a mixture of antibodies
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
SG174053A1
(en)
|
2006-09-01 |
2011-09-29 |
Therapeutic Human Polyclonals Inc |
Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
|
|
CN102123582B
(zh)
*
|
2008-06-27 |
2015-09-30 |
莫鲁斯有限公司 |
产生抗体的非人哺乳动物
|
|
US20110314563A1
(en)
|
2008-12-18 |
2011-12-22 |
Kingdon Craig R |
Antibody production
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
NO2792236T3
(cg-RX-API-DMAC7.html)
|
2009-07-08 |
2018-04-14 |
|
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US20130185821A1
(en)
*
|
2010-02-08 |
2013-07-18 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
US20120021409A1
(en)
*
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
PL3095871T3
(pl)
*
|
2010-02-08 |
2019-10-31 |
Regeneron Pharma |
Mysz zawierająca wspólny łańcuch lekki
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
ME02902B
(me)
*
|
2010-06-22 |
2018-04-20 |
Regeneron Pharma |
Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina
|
|
RS55495B1
(sr)
|
2010-08-02 |
2017-04-28 |
Regeneron Pharma |
Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
|
|
CN105950654B
(zh)
*
|
2010-11-27 |
2020-03-20 |
朱坚 |
一种人源化的转基因动物
|
|
ES2946169T3
(es)
|
2011-02-25 |
2023-07-13 |
Regeneron Pharma |
Ratones ADAM6
|
|
WO2012116927A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
|
MX341921B
(es)
|
2011-02-28 |
2016-09-07 |
Hoffmann La Roche |
Proteinas de union a antigeno.
|
|
IL273982B2
(en)
*
|
2011-08-05 |
2023-03-01 |
Regeneron Pharma |
Humanized mice possess a universal light chain
|
|
EP2758535B1
(en)
|
2011-09-19 |
2016-11-09 |
Kymab Limited |
Antibodies, variable domains&chains tailored for human use
|
|
EP3741862A1
(en)
|
2011-09-19 |
2020-11-25 |
Kymab Limited |
Animals, repertoires & methods for the production of human antibodies
|
|
EP2761008A1
(en)
|
2011-09-26 |
2014-08-06 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
GB2495083A
(en)
*
|
2011-09-26 |
2013-04-03 |
Kymab Ltd |
Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates
|
|
ES2757473T3
(es)
*
|
2011-09-30 |
2020-04-29 |
Dana Farber Cancer Inst Inc |
Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA)
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
KR20250021626A
(ko)
|
2011-10-17 |
2025-02-13 |
리제너론 파마슈티칼스 인코포레이티드 |
제한된 면역글로불린 중쇄 마우스
|
|
US20140283153A1
(en)
|
2011-10-28 |
2014-09-18 |
Trianni, Inc. |
Transgenic animals and methods of use
|
|
US9253965B2
(en)
*
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
BR112014015238B1
(pt)
|
2011-12-20 |
2022-11-16 |
Regeneron Pharmaceuticals, Inc |
Método ex vivo para preparar um anticorpo que se liga a um antígeno de interesse compreendendo identificar sequências de ácido nucleico a partir de linfócitos b de camundongo geneticamente modificado pela colocação de um gene adam6
|
|
BR112014021251A2
(pt)
|
2012-03-02 |
2017-06-27 |
Regeneron Pharma |
anticorpos humanos para toxinas de clostridium difficile
|
|
CA2865029A1
(en)
*
|
2012-03-06 |
2013-09-12 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
CN106318951A
(zh)
*
|
2012-03-16 |
2017-01-11 |
瑞泽恩制药公司 |
生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
|
|
EP3539374A1
(en)
*
|
2012-03-16 |
2019-09-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
AU2015227453B2
(en)
*
|
2012-03-16 |
2017-05-25 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
LT2883449T
(lt)
*
|
2012-03-16 |
2018-05-10 |
Regeneron Pharmaceuticals, Inc. |
Histidinu modifikuoti lengvosios grandinės antikūnai ir juos gaminantys genetiškai modifikuoti graužikai
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
ES2740749T3
(es)
|
2012-04-20 |
2020-02-06 |
Merus Nv |
Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
|
|
CN104583239B
(zh)
|
2012-05-10 |
2018-09-18 |
生物蛋白有限公司 |
多特异单克隆抗体
|
|
AU2013271737A1
(en)
*
|
2012-06-05 |
2015-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for making fully human bispecific antibodies using a common light chain
|
|
MX364449B
(es)
|
2012-06-12 |
2019-04-26 |
Regeneron Pharma |
Animales no humanos humanizados con loci de cadena pesada de inmunoglobulina restringidos.
|
|
WO2014022540A1
(en)
|
2012-08-02 |
2014-02-06 |
Regeneron Pharmaceuticals, Inc. |
Multivalent antigen-binding proteins
|
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
DK2900694T3
(en)
|
2012-09-27 |
2018-11-19 |
Merus Nv |
BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS
|
|
HRP20191865T1
(hr)
|
2013-01-14 |
2020-01-10 |
Xencor, Inc. |
Novi heterodimerni proteini
|
|
KR102714111B1
(ko)
*
|
2013-02-20 |
2024-10-11 |
리제너론 파아마슈티컬스, 인크. |
사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
|
|
EP2840892B1
(en)
|
2013-02-20 |
2018-04-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals with modified immunoglobulin heavy chain sequences
|
|
HRP20181866T1
(hr)
*
|
2013-02-22 |
2019-01-25 |
Regeneron Pharmaceuticals, Inc. |
Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti
|
|
EP4249507A3
(en)
*
|
2013-03-11 |
2023-12-27 |
Regeneron Pharmaceuticals, Inc. |
Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
|
|
EP2970437A1
(en)
*
|
2013-03-13 |
2016-01-20 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
ES2942413T3
(es)
*
|
2013-03-13 |
2023-06-01 |
Regeneron Pharma |
Ratones que expresan un repertorio limitado de cadenas ligeras de inmunoglobulina
|
|
ES2829376T3
(es)
|
2013-03-14 |
2021-05-31 |
Univ Erasmus Med Ct Rotterdam |
Mamífero no humano transgénico para la producción de anticuerpos
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
KR102049990B1
(ko)
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
|
UA118029C2
(uk)
|
2013-04-29 |
2018-11-12 |
Ф. Хоффманн-Ля Рош Аг |
Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US20150033372A1
(en)
*
|
2013-05-01 |
2015-01-29 |
Kymab Limited |
Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
KR20200103882A
(ko)
|
2013-09-18 |
2020-09-02 |
리제너론 파마슈티칼스 인코포레이티드 |
히스티딘 엔지니어링된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-인간 동물
|
|
WO2015046554A1
(ja)
|
2013-09-30 |
2015-04-02 |
中外製薬株式会社 |
改変されたヘルパーファージを用いて抗原結合分子を作製する方法
|
|
SG11201602236SA
(en)
|
2013-10-01 |
2016-04-28 |
Kymab Ltd |
Animal models and therapeutic molecules
|
|
KR20160044060A
(ko)
|
2013-10-11 |
2016-04-22 |
에프. 호프만-라 로슈 아게 |
다중특이적 도메인 교환된 통상의 가변 경쇄 항체
|
|
RU2727639C2
(ru)
|
2014-01-15 |
2020-07-22 |
Ф.Хоффманн-Ля Рош Аг |
Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
|
|
CN110981957B
(zh)
|
2014-01-15 |
2024-12-24 |
豪夫迈·罗氏有限公司 |
具有改善的蛋白A结合作用的Fc区变体
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
*
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
DK3805268T3
(da)
|
2014-02-28 |
2025-01-20 |
Merus Nv |
Antistof, der binder erbb-2 og erbb-3
|
|
US10844127B2
(en)
|
2014-02-28 |
2020-11-24 |
Merus N.V. |
Antibodies that bind EGFR and ErbB3
|
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
RU2016141123A
(ru)
|
2014-03-21 |
2018-04-23 |
Регенерон Фармасьютикалз, Инк. |
Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
|
|
JP6636498B2
(ja)
|
2014-03-21 |
2020-01-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
単一ドメイン結合タンパク質を作る非ヒト動物
|
|
CN106470736B
(zh)
|
2014-05-13 |
2021-05-28 |
宾夕法尼亚州大学信托人 |
包括表达双抗体构建体的aav的组合物及其用途
|
|
PT3151921T
(pt)
|
2014-06-06 |
2019-11-21 |
Bristol Myers Squibb Co |
Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
|
|
US20160081314A1
(en)
|
2014-09-19 |
2016-03-24 |
Regeneron Pharmaceuticals, Inc. |
Chimeric Antigen Receptors
|
|
WO2016054598A2
(en)
|
2014-10-03 |
2016-04-07 |
Massachusetts Institute Of Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
|
EP3842453A1
(en)
|
2014-11-06 |
2021-06-30 |
F. Hoffmann-La Roche AG |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
LT3699198T
(lt)
|
2014-11-17 |
2025-05-12 |
Regeneron Pharmaceuticals, Inc. |
Būdai navikams gydyti naudojant cd3×cd20 bispecifinį antikūną
|
|
ES2807182T3
(es)
|
2014-11-21 |
2021-02-22 |
Bristol Myers Squibb Co |
Anticuerpos frente a CD73 y sus usos
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
RS62332B1
(sr)
|
2014-11-26 |
2021-10-29 |
Xencor Inc |
Heterodimerna antitela koja vezuju cd3 i cd20
|
|
CN107406512A
(zh)
|
2014-11-26 |
2017-11-28 |
Xencor公司 |
结合cd3和cd38的异二聚体抗体
|
|
TWI701258B
(zh)
|
2014-12-19 |
2020-08-11 |
美商再生元醫藥公司 |
流行性感冒病毒血球凝集素之人類抗體
|
|
KR102582807B1
(ko)
|
2014-12-19 |
2023-09-26 |
레제네상스 비.브이. |
인간 c6에 결합하는 항체 및 이의 용도
|
|
JP6180663B2
(ja)
|
2014-12-23 |
2017-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｔｉｇｉｔに対する抗体
|
|
US11111314B2
(en)
|
2015-03-19 |
2021-09-07 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
RS63897B1
(sr)
|
2015-05-29 |
2023-02-28 |
Bristol Myers Squibb Co |
Antitela protiv ox40 i njihova primena
|
|
CA2990015A1
(en)
|
2015-06-29 |
2017-01-05 |
The Rockefeller University |
Antibodies to cd40 with enhanced agonist activity
|
|
MY189159A
(en)
|
2015-07-06 |
2022-01-29 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
JP7010811B2
(ja)
|
2015-07-10 |
2022-02-10 |
メルス ナムローゼ フェンノートシャップ |
ヒトｃｄ３結合抗体
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
SMT202200050T1
(it)
|
2015-09-23 |
2022-03-21 |
Regeneron Pharma |
Anticorpi bispecifici anti-cd3 ottimizzati e loro usi
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
TW202417497A
(zh)
|
2015-10-12 |
2024-05-01 |
美商再生元醫藥公司 |
活化瘦素受體的抗原結合蛋白
|
|
CA3002957A1
(en)
|
2015-10-23 |
2017-04-27 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Binding molecules that inhibit cancer growth
|
|
BR112018010172A2
(pt)
|
2015-11-19 |
2018-11-21 |
Bristol Myers Squibb Co |
anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
|
|
PT3394103T
(pt)
|
2015-12-22 |
2023-09-04 |
Regeneron Pharma |
Combinação de anticorpos anti-pd-1 e anticorpos biespecíj'icos anti-cd20/anti-cd3 para tratar cancro
|
|
SG11201805973WA
(en)
|
2016-01-13 |
2018-08-30 |
Regeneron Pharma |
Rodents having an engineered heavy chain diversity region
|
|
ES2985566T3
(es)
|
2016-03-04 |
2024-11-06 |
Univ Rockefeller |
Anticuerpos contra CD40 con actividad agonista mejorada
|
|
SG10201913033UA
(en)
|
2016-03-04 |
2020-03-30 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
|
EP3448891A1
(en)
|
2016-04-28 |
2019-03-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
WO2017196663A1
(en)
|
2016-05-09 |
2017-11-16 |
Bristol-Myers Squibb Company |
Tl1a antibodies and uses thereof
|
|
TWI755395B
(zh)
|
2016-05-13 |
2022-02-21 |
美商再生元醫藥公司 |
抗-pd-1抗體與輻射治療癌症之組合
|
|
NZ747857A
(en)
|
2016-05-20 |
2023-01-27 |
Regeneron Pharma |
Methods for breaking immunological tolerance using multiple guide rnas
|
|
RS66700B1
(sr)
|
2016-06-03 |
2025-05-30 |
Regeneron Pharma |
Glodari koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu
|
|
MY191668A
(en)
|
2016-06-14 |
2022-07-06 |
Regeneron Pharma |
Anti-c5 antibodies and uses thereof
|
|
BR112018076767A2
(pt)
*
|
2016-06-21 |
2019-04-02 |
Teneobio, Inc. |
anticorpos de ligação a cd3
|
|
CN116063545A
(zh)
|
2016-06-28 |
2023-05-05 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
|
EP4512829A3
(en)
|
2016-07-14 |
2025-06-11 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
UY37377A
(es)
|
2016-08-26 |
2018-03-23 |
Sanofi Sa |
Anticuerpos multiespecíficos que facilitan el emparejamiento selectivo de cadenas ligeras
|
|
US10981976B2
(en)
|
2016-08-31 |
2021-04-20 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
|
|
FI4050034T3
(fi)
|
2016-09-14 |
2024-06-10 |
Teneoone Inc |
Cd3:een sitoutuvia vasta-aineita
|
|
NZ751906A
(en)
|
2016-09-23 |
2025-10-31 |
Regeneron Pharma |
Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
|
|
PL3515946T3
(pl)
|
2016-09-23 |
2022-11-07 |
Regeneron Pharmaceuticals, Inc. |
Przeciwciała anty-muc16 (mucyna 16)
|
|
SG10201912925SA
(en)
|
2016-10-13 |
2020-02-27 |
Massachusetts Inst Technology |
Antibodies that bind zika virus envelope protein and uses thereof
|
|
IL267485B2
(en)
|
2016-12-21 |
2024-01-01 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies and uses thereof
|
|
BR112019016336A2
(pt)
|
2017-02-10 |
2020-03-31 |
Regeneron Pharmaceuticals, Inc. |
Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
|
|
EP3583124A1
(en)
|
2017-02-17 |
2019-12-25 |
Bristol-Myers Squibb Company |
Antibodies to alpha-synuclein and uses thereof
|
|
EP3589650A1
(en)
|
2017-03-02 |
2020-01-08 |
Novartis AG |
Engineered heterodimeric proteins
|
|
EP3600413A1
(en)
|
2017-03-31 |
2020-02-05 |
Merus N.V. |
Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
KR102744809B1
(ko)
|
2017-05-17 |
2024-12-23 |
메뤼스 엔.페. |
유방암 치료를 위한 ErbB-2/ErbB-3 이중특이적 항체와 내분비 치료의 조합
|
|
MY198804A
(en)
|
2017-06-07 |
2023-09-28 |
Regeneron Pharma |
Compositions and methods for internalizing enzymes
|
|
KR20250007003A
(ko)
|
2017-06-20 |
2025-01-13 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
CN118146370A
(zh)
|
2017-06-20 |
2024-06-07 |
特纳奥尼股份有限公司 |
仅有重链的抗bcma抗体
|
|
GB201710984D0
(en)
*
|
2017-07-07 |
2017-08-23 |
Kymab Ltd |
Cells, vertebrates, populations & methods
|
|
TWI865430B
(zh)
|
2017-07-24 |
2024-12-11 |
美商再生元醫藥公司 |
穩定化之抗體組合物及其製法
|
|
PL3665198T3
(pl)
|
2017-08-09 |
2025-06-09 |
Merus N.V. |
Przeciwciała wiążące egfr i cmet
|
|
US10865236B2
(en)
|
2017-09-29 |
2020-12-15 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
|
|
CN112272563A
(zh)
|
2017-11-08 |
2021-01-26 |
Xencor股份有限公司 |
使用新颖抗pd-1序列的双特异性和单特异性抗体
|
|
IL275264B1
(en)
|
2017-12-13 |
2025-10-01 |
Regeneron Pharma |
Anti-C5 antibody combinations and their uses
|
|
MX2020006494A
(es)
|
2017-12-22 |
2020-11-24 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen a cd22.
|
|
WO2019140229A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
MX2020007772A
(es)
|
2018-01-26 |
2020-09-18 |
Regeneron Pharma |
Anticuerpos humanos contra hemaglutinina de influenza.
|
|
TW202003565A
(zh)
|
2018-03-23 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
抗mica及/或micb抗體及其用途
|
|
EP3772927B1
(en)
|
2018-03-24 |
2025-01-15 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
|
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
EP4596043A3
(en)
|
2018-04-06 |
2025-10-01 |
Regeneron Pharmaceuticals, Inc. |
A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia
|
|
JP7328990B2
(ja)
|
2018-04-30 |
2023-08-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
|
|
CN112135624B
(zh)
|
2018-05-17 |
2024-07-19 |
瑞泽恩制药公司 |
抗cd63抗体、缀合物和其用途
|
|
CA3103414A1
(en)
|
2018-06-14 |
2019-12-19 |
Bioatla, Inc. |
Multi-specific antibody constructs
|
|
IL318469A
(en)
|
2018-06-14 |
2025-03-01 |
Regeneron Pharma |
Non-human animals capable of reorganizing transgenic DH-DH, and their uses
|
|
MX419677B
(es)
|
2018-06-21 |
2025-01-14 |
Regeneron Pharma |
Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
BR112021003023A2
(pt)
|
2018-08-23 |
2021-05-11 |
Regeneron Pharmaceuticals, Inc. |
anticorpos anti-fc epsilon-r1 alfa (fcer1a), moléculas biespecíficas de ligação ao antígeno que ligam fcer1a e cd3, e usos dos mesmos
|
|
FI3844189T3
(fi)
|
2018-08-31 |
2025-03-05 |
Regeneron Pharma |
Annostusstrategia, joka lieventää bispesifisten CD3/CD20-vasta-aineiden sytokiinien vapautumisoireyhtymää
|
|
WO2020086406A2
(en)
|
2018-10-23 |
2020-04-30 |
Regeneron Pharmaceuticals, Inc. |
Anti-npr1 antibodies and uses thereof
|
|
PE20211284A1
(es)
|
2018-11-16 |
2021-07-19 |
Bristol Myers Squibb Co |
Anticuerpos anti-nkg2a y usos de los mismos
|
|
EP3883961A1
(en)
|
2018-11-20 |
2021-09-29 |
Takeda Vaccines, Inc. |
Novel anti-zika virus antibodies and uses thereof
|
|
CA3110377A1
(en)
|
2018-11-21 |
2020-05-28 |
Regeneron Pharmaceuticals, Inc. |
Anti-staphylococcus antibodies and uses thereof
|
|
CN113164598B
(zh)
|
2018-12-19 |
2025-04-25 |
里珍纳龙药品有限公司 |
双特异性抗cd28 x抗cd22抗体以及其用途
|
|
WO2020132024A1
(en)
|
2018-12-19 |
2020-06-25 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
|
|
US12467062B2
(en)
|
2018-12-21 |
2025-11-11 |
Compass Therapeutics Llc |
Transgenic mouse expressing common human light chain
|
|
CN113396162B
(zh)
|
2019-01-22 |
2024-08-16 |
百时美施贵宝公司 |
抗IL-7Rα亚基的抗体及其用途
|
|
JP2022519631A
(ja)
|
2019-02-12 |
2022-03-24 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
補体および標的抗原に結合する二重特異性抗体を使用するための組成物および方法
|
|
CA3125380A1
(en)
|
2019-02-18 |
2020-08-27 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Genetically modified non-human animals with humanized immunoglobulin locus
|
|
SG11202107589PA
(en)
|
2019-02-22 |
2021-08-30 |
Regeneron Pharma |
Rodents having genetically modified sodium channels and methods of use thereof
|
|
WO2020198009A1
(en)
|
2019-03-22 |
2020-10-01 |
Regeneron Pharmaceuticals, Inc. |
EGFR x CD28 MULTISPECIFIC ANTIBODIES
|
|
AU2020252556A1
(en)
|
2019-04-05 |
2021-10-21 |
Teneobio, Inc. |
Heavy chain antibodies binding to PSMA
|
|
US20220330532A1
(en)
|
2019-06-05 |
2022-10-20 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
|
|
US11655286B2
(en)
|
2019-06-11 |
2023-05-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof
|
|
AR119746A1
(es)
|
2019-06-14 |
2022-01-05 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
|
AU2020296181A1
(en)
|
2019-06-21 |
2021-12-16 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind PSMA and CD3 in combination with 4-1BB co-stimulation
|
|
AU2020294790A1
(en)
|
2019-06-21 |
2021-12-16 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
|
|
EP4010371A1
(en)
|
2019-08-08 |
2022-06-15 |
Regeneron Pharmaceuticals, Inc. |
Novel antigen binding molecule formats
|
|
KR20220044821A
(ko)
|
2019-08-15 |
2022-04-11 |
리제너론 파아마슈티컬스, 인크. |
세포 표적화를 위한 다중특이적 항원-결합 분자 및 이의 용도
|
|
GB201912008D0
(en)
|
2019-08-21 |
2019-10-02 |
Cambridge Entpr Ltd |
Antibody
|
|
JP7611908B2
(ja)
|
2019-10-28 |
2025-01-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗血球凝集素抗体およびその使用方法
|
|
JP7726881B2
(ja)
|
2019-12-02 |
2025-08-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
|
|
WO2021113701A1
(en)
|
2019-12-06 |
2021-06-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
MX2022009769A
(es)
|
2020-02-11 |
2022-11-09 |
Regeneron Pharma |
Anticuerpos anti-acvr1 y usos de los mismos.
|
|
BR112022021690A2
(pt)
|
2020-04-29 |
2022-12-20 |
Teneobio Inc |
Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
|
|
WO2021231366A1
(en)
|
2020-05-12 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Anti-glp1r antagonist antibodies and methods of use thereof
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
IL298632A
(en)
*
|
2020-06-02 |
2023-01-01 |
Biocytogen Pharmaceuticals Beijing Co Ltd |
Non-human animals genetically modified with a common light chain immunoglobulin locus
|
|
US11919958B2
(en)
|
2020-08-19 |
2024-03-05 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
TW202229328A
(zh)
|
2020-09-11 |
2022-08-01 |
美商再生元醫藥公司 |
抗原特異性抗體之鑑定及產生
|
|
US11905332B2
(en)
|
2020-09-18 |
2024-02-20 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof
|
|
EP4232481A1
(en)
|
2020-10-22 |
2023-08-30 |
Regeneron Pharmaceuticals, Inc. |
Anti-fgfr2 antibodies and methods of use thereof
|
|
CN114524878B
(zh)
|
2020-11-23 |
2024-08-02 |
康诺亚生物医药科技（成都）有限公司 |
一种双特异性抗体及其用途
|
|
JP2024500399A
(ja)
|
2020-12-16 |
2024-01-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化Ｆｃアルファ受容体を発現するマウス
|
|
US12325752B2
(en)
|
2020-12-18 |
2025-06-10 |
Regeneron Pharmaceuticals, Inc. |
Immunoglobulin proteins that bind to NPR1 agonists
|
|
US12371475B2
(en)
|
2020-12-23 |
2025-07-29 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding anchor modified antibodies and uses thereof
|
|
IL303865A
(en)
|
2020-12-23 |
2023-08-01 |
Regeneron Pharma |
Methods for obtaining antibodies that bind transmembrane proteins and cells that produce them
|
|
KR20230157315A
(ko)
|
2021-01-28 |
2023-11-16 |
리제너론 파마슈티칼스 인코포레이티드 |
사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법
|
|
KR20230156079A
(ko)
|
2021-03-09 |
2023-11-13 |
젠코어 인코포레이티드 |
Cd3과 cldn6에 결합하는 이종이량체 항체
|
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
|
JP2024512702A
(ja)
|
2021-03-31 |
2024-03-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｔｃｒβレパートリーの改善された多様性を伴うヒト化細胞免疫系の構成要素を含む、遺伝的に改変されたマウス
|
|
AU2022408149A1
(en)
|
2021-12-06 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Antagonist anti-npr1 antibodies and methods of use thereof
|
|
IL314993A
(en)
|
2022-02-23 |
2024-10-01 |
Xencor Inc |
Anti-cd28 x anti-psma antibodies
|
|
TW202400228A
(zh)
|
2022-02-25 |
2024-01-01 |
美商再生元醫藥公司 |
減輕細胞激素釋放症候群的給藥方案
|
|
WO2023196903A1
(en)
|
2022-04-06 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
|
|
IL316002A
(en)
|
2022-04-11 |
2024-11-01 |
Regeneron Pharma |
Compositions and methods for universal tumor cell killing
|
|
WO2023225098A1
(en)
|
2022-05-18 |
2023-11-23 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
|
|
WO2024015816A1
(en)
|
2022-07-12 |
2024-01-18 |
Regeneron Pharmaceuticals, Inc. |
Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
|
|
US20240150474A1
(en)
|
2022-10-27 |
2024-05-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification
|
|
GB202217978D0
(en)
*
|
2022-11-30 |
2023-01-11 |
Petmedix Ltd |
Rodents expressing a common light chain
|
|
TW202430641A
(zh)
|
2023-01-18 |
2024-08-01 |
美商基利科學股份有限公司 |
人類免疫球蛋白二元輕鏈轉殖基因構築體及其用途
|
|
EP4658687A1
(en)
|
2023-01-31 |
2025-12-10 |
University of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
KR20250150011A
(ko)
|
2023-02-13 |
2025-10-17 |
리제너론 파마슈티칼스 인코포레이티드 |
항-인간 cacng1 항체를 이용한 근육 관련 장애 치료
|
|
EP4665385A2
(en)
|
2023-02-17 |
2025-12-24 |
Regeneron Pharmaceuticals, Inc. |
Induced nk cells responsive to cd3/taa bispecific antibodies
|
|
CN121039163A
(zh)
|
2023-05-02 |
2025-11-28 |
瑞泽恩制药公司 |
抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
|
|
WO2024259206A1
(en)
|
2023-06-16 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Cd40 x cd40 bispecific antigen-binding molecules and uses thereof
|
|
WO2025014533A1
(en)
|
2023-07-10 |
2025-01-16 |
Regeneron Pharmaceuticals, Inc. |
Anti-human cacng1 antibody-drug conjugates and uses thereof
|
|
TW202519547A
(zh)
|
2023-07-10 |
2025-05-16 |
美商再生元醫藥公司 |
雙特異性PD-L1x4-1BB抗體及其使用方法
|
|
TW202519559A
(zh)
|
2023-07-10 |
2025-05-16 |
美商再生元醫藥公司 |
雙特異性PD-L1xCD28抗體及其使用方法
|
|
EP4630457A1
(en)
|
2023-08-18 |
2025-10-15 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules and uses thereof
|
|
WO2025064761A1
(en)
|
2023-09-22 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Kras10-18 g12d off-target peptides and uses thereof
|
|
WO2025064738A1
(en)
|
2023-09-22 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Dntt 250-258 off-target peptides and uses thereof
|
|
US20250242056A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
WO2025160340A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
US20250277048A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025199278A2
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Masked multispecific antigen-binding molecules with cleavable linkers
|